What “success rate” usually means for Dupixent
“Dupixent success rate” can refer to different outcomes depending on the condition, such as how many people achieve a key clinical endpoint (like symptom score improvement), how many respond early, or how many stay on treatment long enough to see benefit. Reported success rates vary by disease area (asthma, atopic dermatitis/eczema, chronic rhinosinusitis with nasal polyps, and other indications) and by the specific trial endpoint used.
If you share which condition you mean, I can narrow the figures to the most relevant endpoints.
Dupixent for eczema (atopic dermatitis): what response rates look like in trials
For atopic dermatitis, “success” is commonly reported as the proportion of patients who reach a predefined improvement on a symptoms/skin severity scale (for example, a 75% improvement or similar thresholds at a set week). The overall “success rate” depends on:
- Baseline severity and whether patients are treatment-naïve or have used other therapies
- Whether Dupixent is used alone or with other meds
- The endpoint definition used in the trial and the time point (week 16, week 24, etc.)
Dupixent for asthma: how “success rate” is typically measured
In asthma studies, success rates are often tied to outcomes like:
- Fewer severe exacerbations compared with placebo
- Improvement in lung function measures and symptom control scores
- The proportion of patients who maintain control over a study period
Different asthma phenotypes (for example, with type 2 inflammation markers) can show different response magnitudes.
Dupixent for nasal polyps (with chronic rhinosinusitis): response endpoints
For chronic rhinosinusitis with nasal polyps, success is usually reported using:
- Improvements in nasal polyp scores
- Reduced need for systemic steroids and/or better symptom scores over time
“Success rate” depends heavily on the specific endpoint and follow-up duration used in the trial.
Why you might see different “success rates” for the same drug
Even for the same indication, published response numbers can differ because of:
- The exact endpoint (symptom improvement vs. reduction in exacerbations)
- Time to assessment (early vs. later outcomes)
- Patient selection (baseline disease severity, prior treatment history, comorbidities)
If you’re asking for a real-world success rate
Clinical trials report efficacy under controlled conditions. Real-world “success” can be lower because patients discontinue for reasons like side effects, lack of perceived benefit, access or insurance barriers, or adherence issues.
If you tell me whether you mean clinical-trial success or real-world likelihood, I can tailor the answer.
Quick clarification so I can give the right numbers
Which Dupixent indication do you mean?
1) Eczema/atopic dermatitis
2) Asthma
3) Chronic rhinosinusitis with nasal polyps
4) Another condition
Also, when you say “success rate,” do you mean symptom improvement, fewer flare-ups/exacerbations, or treatment continuation?